Could age modify the effect of genetic variants in IL6 and TNF-α genes in multiple myeloma?

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 594-597

  Martino, Alessandro ^a,c   Buda, Gabriele ^a   Maggini, Valentina ^b   Lapi, Francesco ^b   Lupia, Antonella ^a   Di Bello, Domenica ^a   Orciuolo, Enrico ^a   Galimberti, Sara ^a   Barale, Roberto ^a   Petrini, Mario ^a   Rossi, Anna Maria ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Genetic susceptibility; IL6; Inflammation; Multiple myeloma; Pharmacogenetics; SNP; TNF

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CREATININE; HEMOGLOBIN; MELPHALAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RISK; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTERLEUKIN 6 GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR ALPHA GENE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENETIC VARIATION; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858752029     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.02.009     Document Type: Article

References (13)

1. Landgren O., Weiss B.M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009, 23(October (10)):1691-1697.
2. Lauta V.M. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003, 97(May 15 (10)):2440-2452.
3. Martino A., Sainz J., Buda G., Jamroziak K., Reis R.M., García-Sanz R., et al. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J Oncol 2011, December 6. doi: 10.3892/ijo.2011.1284.
4. Kádár K., Kovács M., Karádi I., Melegh B., Pocsai Z., Mikala G., et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res 2008 Oct, 32(10):1499-1504.
5. Seruga B., Zhang H., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008, 8(November (11)):887-899.
6. Chung H.Y., Sung B., Jung K.J., Zou Y., Yu B.P. The molecular inflammatory process in aging. Antioxid Redox Signal 2006, 8(March-April (3-4)):572-581.
7. Vasto S., Carruba G., Lio D., Colonna-Romano G., Di Bona D., Candore G., et al. Inflammation, ageing and cancer. Mech Ageing Dev 2009, 130(January-February (1-2)):40-45.
8. Di Bona D., Vasto S., Capurso C., Christiansen L., Deiana L., Franceschi C., et al. Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. Ageing Res Rev 2009, 8(January (1)):36-42.
9. Landi S., Moreno V., Gioia-Patricola L., Guino E., Navarro M., de Oca J., et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003, 63(July 1 (13)):3560-3566.
10. Olivieri F., Bonafè M., Cavallone L., Giovagnetti S., Marchegiani F., Cardelli M., et al. The -174C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol 2002, 37(January-March (2-3)):309-314.
11. Villuendas G., San Millan J.L., Sancho J., Escobar-Morreale H.F. The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002, 87(March (3)):1134-1141.
12. Urbańska-RyŚ H., Wiersbowska A., Stepień H., Robak T. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur Cytokine Netw 2000, 11(September (3)):443-451.
13. Davies F.E., Rollinson S.J., Rawstron A.C., Roman E., Richards S., Drayson M., et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 2000, 18(August (15)):2843-2851.